The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials - PubMed (original) (raw)
Meta-Analysis
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
Cholesterol Treatment Trialists' (CTT) Collaborators et al. Lancet. 2012.
Abstract
Background: Statins reduce LDL cholesterol and prevent vascular events, but their net effects in people at low risk of vascular events remain uncertain.
Methods: This meta-analysis included individual participant data from 22 trials of statin versus control (n=134,537; mean LDL cholesterol difference 1·08 mmol/L; median follow-up 4·8 years) and five trials of more versus less statin (n=39,612; difference 0·51 mmol/L; 5·1 years). Major vascular events were major coronary events (ie, non-fatal myocardial infarction or coronary death), strokes, or coronary revascularisations. Participants were separated into five categories of baseline 5-year major vascular event risk on control therapy (no statin or low-intensity statin) (<5%, ≥5% to <10%, ≥10% to <20%, ≥20% to <30%, ≥30%); in each, the rate ratio (RR) per 1·0 mmol/L LDL cholesterol reduction was estimated.
Findings: Reduction of LDL cholesterol with a statin reduced the risk of major vascular events (RR 0·79, 95% CI 0·77-0·81, per 1·0 mmol/L reduction), largely irrespective of age, sex, baseline LDL cholesterol or previous vascular disease, and of vascular and all-cause mortality. The proportional reduction in major vascular events was at least as big in the two lowest risk categories as in the higher risk categories (RR per 1·0 mmol/L reduction from lowest to highest risk: 0·62 [99% CI 0·47-0·81], 0·69 [99% CI 0·60-0·79], 0·79 [99% CI 0·74-0·85], 0·81 [99% CI 0·77-0·86], and 0·79 [99% CI 0·74-0·84]; trend p=0·04), which reflected significant reductions in these two lowest risk categories in major coronary events (RR 0·57, 99% CI 0·36-0·89, p=0·0012, and 0·61, 99% CI 0·50-0·74, p<0·0001) and in coronary revascularisations (RR 0·52, 99% CI 0·35-0·75, and 0·63, 99% CI 0·51-0·79; both p<0·0001). For stroke, the reduction in risk in participants with 5-year risk of major vascular events lower than 10% (RR per 1·0 mmol/L LDL cholesterol reduction 0·76, 99% CI 0·61-0·95, p=0·0012) was also similar to that seen in higher risk categories (trend p=0·3). In participants without a history of vascular disease, statins reduced the risks of vascular (RR per 1·0 mmol/L LDL cholesterol reduction 0·85, 95% CI 0·77-0·95) and all-cause mortality (RR 0·91, 95% CI 0·85-0·97), and the proportional reductions were similar by baseline risk. There was no evidence that reduction of LDL cholesterol with a statin increased cancer incidence (RR per 1·0 mmol/L LDL cholesterol reduction 1·00, 95% CI 0·96-1·04), cancer mortality (RR 0·99, 95% CI 0·93-1·06), or other non-vascular mortality.
Interpretation: In individuals with 5-year risk of major vascular events lower than 10%, each 1 mmol/L reduction in LDL cholesterol produced an absolute reduction in major vascular events of about 11 per 1000 over 5 years. This benefit greatly exceeds any known hazards of statin therapy. Under present guidelines, such individuals would not typically be regarded as suitable for LDL-lowering statin therapy. The present report suggests, therefore, that these guidelines might need to be reconsidered.
Funding: British Heart Foundation; UK Medical Research Council; Cancer Research UK; European Community Biomed Programme; Australian National Health and Medical Research Council; National Heart Foundation, Australia.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Figures
Figure 1
Effects on major coronary events, strokes, coronary revascularisation procedures, and major vascular events per 1·0 mmol/L reduction in LDL cholesterol at different levels of risk MVE=major vascular event. RR=rate ratio. CI=confidence interval.
Figure 2
Effects on major vascular events per 1·0 mmol/L reduction in LDL cholesterol at different levels of risk, by history of vascular disease MVE=major vascular event. RR=rate ratio. CI=confidence interval.
Figure 3
Effects on vascular and non-vascular deaths per 1·0 mmol/L reduction in LDL cholesterol at different levels of risk, by history of vascular disease MVE=major vascular event. RR=rate ratio. CI=confidence interval. There were a further 179 (statin/more statin) versus 210 (control/less statin) deaths of unknown cause among participants without vascular disease and 309 (statin/more statin) versus 338 (control/less statin) deaths of unknown cause among participants with vascular disease.
Figure 4
Effects on cancer incidence and cancer mortality per 1·0 mmol/L reduction in LDL cholesterol at different levels of risk MVE=major vascular event. RR=rate ratio. CI=confidence interval.
Figure 5
Predicted 5-year benefits of LDL cholesterol reductions with statin treatment at different levels of risk (A) Major vascular events and (B) vascular deaths. Lifetable estimates using major vascular event risk or vascular death risk in the respective risk categories and overall treatment effects per 1·0 mmol/L reduction in LDL cholesterol with statin.
Comment in
- Statins for all by the age of 50 years?
Ebrahim S, Casas JP. Ebrahim S, et al. Lancet. 2012 Aug 11;380(9841):545-7. doi: 10.1016/S0140-6736(12)60694-1. Epub 2012 May 17. Lancet. 2012. PMID: 22607823 No abstract available. - Vascular disease: Even low-risk individuals can benefit from statin therapy.
Lim GB. Lim GB. Nat Rev Cardiol. 2012 Jun 5;9(7):371. doi: 10.1038/nrcardio.2012.79. Nat Rev Cardiol. 2012. PMID: 22665328 No abstract available. - ACP Journal Club. Meta-analysis: lowering LDL-C levels using statins reduces major vascular events regardless of baseline risk.
Jain M, Rosenberg M. Jain M, et al. Ann Intern Med. 2012 Oct 16;157(8):JC4-2. doi: 10.7326/0003-4819-157-8-201210160-02002. Ann Intern Med. 2012. PMID: 23070504 No abstract available. - Statins for people at low risk of cardiovascular disease.
Newman DH, Saini V, Brody H, Brownlee S, Hoffman JR, Redberg RF, Roberts BH. Newman DH, et al. Lancet. 2012 Nov 24;380(9856):1814; author reply 1817-8. doi: 10.1016/S0140-6736(12)62020-0. Lancet. 2012. PMID: 23177692 No abstract available. - Statins for people at low risk of cardiovascular disease.
Donzelli A. Donzelli A. Lancet. 2012 Nov 24;380(9856):1814-5; author reply 1817-8. doi: 10.1016/S0140-6736(12)62021-2. Lancet. 2012. PMID: 23177693 No abstract available. - Statins for people at low risk of cardiovascular disease.
Battaggia A, Font M. Battaggia A, et al. Lancet. 2012 Nov 24;380(9856):1815; author reply 1817-8. doi: 10.1016/S0140-6736(12)62022-4. Lancet. 2012. PMID: 23177694 No abstract available. - Statins for people at low risk of cardiovascular disease.
Simpson WG. Simpson WG. Lancet. 2012 Nov 24;380(9856):1815-6; author reply 1817-8. doi: 10.1016/S0140-6736(12)62023-6. Lancet. 2012. PMID: 23177695 No abstract available. - Statins for people at low risk of cardiovascular disease.
Ray KK, Redberg RF. Ray KK, et al. Lancet. 2012 Nov 24;380(9856):1816; author reply 1817-8. doi: 10.1016/S0140-6736(12)62024-8. Lancet. 2012. PMID: 23177696 No abstract available. - Statins for people at low risk of cardiovascular disease.
Mascitelli L, Goldstein MR. Mascitelli L, et al. Lancet. 2012 Nov 24;380(9856):1816; author reply 1817-8. doi: 10.1016/S0140-6736(12)62025-X. Lancet. 2012. PMID: 23177697 No abstract available. - Statins for people at low risk of cardiovascular disease.
Zomer E, Owen AJ, Magliano DJ, Reid CM. Zomer E, et al. Lancet. 2012 Nov 24;380(9856):1817; author reply 1817-8. doi: 10.1016/S0140-6736(12)62026-1. Lancet. 2012. PMID: 23177699 No abstract available. - Statins for people at low risk of cardiovascular disease.
Wald N, Law M. Wald N, et al. Lancet. 2012 Nov 24;380(9856):1818. doi: 10.1016/S0140-6736(12)62028-5. Lancet. 2012. PMID: 23177700 No abstract available. - [Statin therapy in low-risk cardiac patients is particularly effective].
Glatz U. Glatz U. Dtsch Med Wochenschr. 2012 Oct;137(42):2136. doi: 10.1055/s-0032-1328976. Dtsch Med Wochenschr. 2012. PMID: 23227522 German. No abstract available. - Remediating "Lessons from the controversy over statins".
Abramson J, Rosenberg HG, Jewell N, Wright JM. Abramson J, et al. Lancet. 2017 Mar 18;389(10074):1101-1102. doi: 10.1016/S0140-6736(17)30720-1. Lancet. 2017. PMID: 28322818 No abstract available. - Evolocumab and clinical outcomes in patients with cardiovascular disease.
Hadjiphilippou S, Ray KK. Hadjiphilippou S, et al. J R Coll Physicians Edinb. 2017 Jun;47(2):153-155. doi: 10.4997/JRCPE.2017.212. J R Coll Physicians Edinb. 2017. PMID: 28675189 No abstract available.
Similar articles
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Cholesterol Treatment Trialists’ (CTT) Collaboration, et al. Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8. Lancet. 2010. PMID: 21067804 Free PMC article. - Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.
Cholesterol Treatment Trialists' Collaboration. Cholesterol Treatment Trialists' Collaboration. Lancet. 2019 Feb 2;393(10170):407-415. doi: 10.1016/S0140-6736(18)31942-1. Lancet. 2019. PMID: 30712900 Free PMC article. - Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.
Cholesterol Treatment Trialists' (CTT) Collaboration; Herrington WG, Emberson J, Mihaylova B, Blackwell L, Reith C, Solbu MD, Mark PB, Fellström B, Jardine AG, Wanner C, Holdaas H, Fulcher J, Haynes R, Landray MJ, Keech A, Simes J, Collins R, Baigent C. Cholesterol Treatment Trialists' (CTT) Collaboration, et al. Lancet Diabetes Endocrinol. 2016 Oct;4(10):829-39. doi: 10.1016/S2213-8587(16)30156-5. Epub 2016 Jul 29. Lancet Diabetes Endocrinol. 2016. PMID: 27477773 - Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. Silverman MG, et al. JAMA. 2016 Sep 27;316(12):1289-97. doi: 10.1001/jama.2016.13985. JAMA. 2016. PMID: 27673306 Review. - Interpretation of the evidence for the efficacy and safety of statin therapy.
Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Collins R, et al. Lancet. 2016 Nov 19;388(10059):2532-2561. doi: 10.1016/S0140-6736(16)31357-5. Epub 2016 Sep 8. Lancet. 2016. PMID: 27616593 Review.
Cited by
- Impact of non-traditional lipid profiles on 1-year vascular outcomes in ischemic stroke patients with prior statin therapy and LDL-C < 100 mg/dL.
Kim H, Kim JT, Lee JS, Kim BJ, Kang J, Lee KJ, Park JM, Kang K, Lee SJ, Kim JG, Cha JK, Kim DH, Park TH, Lee K, Lee J, Hong KS, Cho YJ, Park HK, Lee BC, Yu KH, Oh MS, Kim DE, Choi JC, Kwon JH, Kim WJ, Shin DI, Yum KS, Sohn SI, Hong JH, Lee SH, Park MS, Ryu WS, Park KY, Lee J, Saver JL, Bae HJ. Kim H, et al. Sci Rep. 2024 Oct 1;14(1):22794. doi: 10.1038/s41598-024-73851-5. Sci Rep. 2024. PMID: 39354143 Free PMC article. - Polypills in the Management of Cardiovascular Risk-A Perspective.
de Abreu-Silva EO, Siepmann M, Siepmann T. de Abreu-Silva EO, et al. J Clin Med. 2024 Sep 16;13(18):5487. doi: 10.3390/jcm13185487. J Clin Med. 2024. PMID: 39336974 Free PMC article. - [A conceptual framework for good preventive practices (or for quaternary prevention)].
Tesser CD. Tesser CD. Cad Saude Publica. 2024 Sep 16;40(8):e00068123. doi: 10.1590/0102-311XPT068123. eCollection 2024. Cad Saude Publica. 2024. PMID: 39292133 Free PMC article. Portuguese. - Low LDL-C: Is It all Good News?
Hartz J. Hartz J. Curr Atheroscler Rep. 2024 Sep 10. doi: 10.1007/s11883-024-01238-y. Online ahead of print. Curr Atheroscler Rep. 2024. PMID: 39254830 Review. - Prevalence and associated factors of non-adherence to antihyperlipidemic medication: a nationwide cross sectional survey in Pakistan.
Arshed M, Umer MF, Kiran M, Akhter AM, Gillani AH, Qamer S, Kawish AB, Zofeen S, Farid A, Khan MN. Arshed M, et al. Sci Rep. 2024 Sep 4;14(1):20613. doi: 10.1038/s41598-024-71120-z. Sci Rep. 2024. PMID: 39232055 Free PMC article.
References
- Ray KK, Seshasai SR, Erqou S. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170:1024–1031. - PubMed
- Redberg RF, Katz M, Grady D. Editor's Note—to make the case—evidence is required: comment on “Making the case for selective use of statins in the primary prevention setting”. Arch Intern Med. 2011;171:1594. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- G0701113/MRC_/Medical Research Council/United Kingdom
- MC_U137686849/MRC_/Medical Research Council/United Kingdom
- PG/08/063/25397/BHF_/British Heart Foundation/United Kingdom
- CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical